This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Catalyst's Firdapse Receives FDA Approval for Rare Disease
by Zacks Equity Research
Catalyst's (CPRX) Firdapse gets FDA approval for the treatment of LEMS in adults.
4 Big Pharma Stocks to Add to Your Portfolio in December
by Kinjel Shah
The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.
Top Stock Reports for Merck, Mastercard & Salesforce
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Mastercard (MA) and Salesforce (CRM).
Pfizer's Epilepsy Drug Lyrica Gets Pediatric Exclusivity
by Zacks Equity Research
Pfizer (PFE) receives pediatric exclusivity for its epilepsy drug, Lyrica, extending the exclusivity period to Jun 30, 2019.
Accenture Brings Open Partner Ecosystem for Drug Discovery
by Zacks Equity Research
The ecosystem backed by cloud-based informatics research platform is likely to drive Accenture's (ACN) Products Segment.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $76.34 in the latest trading session, marking a +1.19% move from the prior day.
Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate
by Zacks Equity Research
Alnylam (ALNY) and Vir commence phase I/II study for VIR-2218 for the treatment of chronic HBV infection.
Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial
by Zacks Equity Research
Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with Yervoy fails to meet the goal in a late-stage study for extensive-stage SCLC.
Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease
by Zacks Equity Research
AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.
AMAG's Label Expansion of Lead Products Raises Share Price
by Zacks Equity Research
AMAG's (AMAG) label expansion efforts for Feraheme and Makena are encouraging.
Glaxo Inks Marketing Deal for Anaemia Candidate in Japan
by Zacks Equity Research
GlaxoSmithKline (GSK) signs a collaboration contract with Japan's Kyowa Hakko Kirin for future commercialization of daprodustat in Japan.
Bayer Hurts from Generic Competition & Pipeline Setbacks
by Zacks Equity Research
Bayer (BAYRY) faces pipeline setbacks. Weak global economy outlook and generic competition are headwinds.
Pfizer's FDA Nod for Cancer Drug is Four in a Row in 90 Days
by Zacks Equity Research
Pfizer (PFE) wins an FDA nod for Daurismo in combination with low-dose cytarabine regarding newly-diagnosed AML in adults. This is the fourth cancer drug approval on the trot in less than 90 days.
New Trends in Healthcare Push Stocks Higher: 5 Picks
by Zacks Equity Research
New healthcare trends backed by split party control of Congress are likely to boost industry stocks.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $74.79, marking a +0.01% move from the previous day.
Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility
by Zacks Equity Research
Mylan (MYL) recalls batches of blood pressure medicine in the United States. The company receives warning letter from the FDA for the manufacturing facility in Morgantown, WV.
IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts IntelGenx's (IGXT) NDA resubmssion for its migraine candidate Rizaport 10 mg. The stock appreciates.
FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz
by Zacks Equity Research
The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Shire-Takeda Deal Gets Phase I Conditional European Approval
by Zacks Equity Research
Takeda's bid to acquire Shire (SHPG) receives conditional approval from the European Commission.
TESARO Shares Rally on Rumors of Potential Acquisition Offer
by Zacks Equity Research
Per a Bloomberg report, TESARO (TSRO) may have received an acquisition offer. Shares rally on rumors.
Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails
by Zacks Equity Research
Pfizer's (PFE) late-stage advanced ovarian study on Bavencio (avelumab) fails to meet the primary endpoints.
AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) announced that Imfinzi as a monotherapy or in combination with tremelimumab failed to improve overall survival in first-line NSCLC. The combination had also failed to improve progression free survival last year.
Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs
by Zacks Equity Research
Per a Wall Street report, Pfizer (PFE) plans to increase the list prices of its 41 prescription drugs in 2019.
Bristol-Myers' Opdivo Receives Positive CHMP Opinion for RCC
by Zacks Equity Research
Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with low-dose Yervoy gets positive opinion from CHMP for the treatment of intermediate- and poor-risk advanced RCC.
Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
by Zacks Equity Research
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.